Sort   by:  
 Page size 
UnknownInteraction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial.
Not available
S-EPMC12547913 | biostudies-literature
UnknownTumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial.
Not available
S-EPMC11826437 | biostudies-literature
UnknownAssociation of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Not available
S-EPMC6442655 | biostudies-literature
UnknownNine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
Not available
S-EPMC10642895 | biostudies-literature
UnknownValidation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Not available
S-EPMC6868696 | biostudies-literature
Sort   by:  
 Page size